Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Janssen Pharmaceuticals
Information provided by (Responsible Party):
Duke University
ClinicalTrials.gov Identifier:
NCT01717053
First received: October 26, 2012
Last updated: September 12, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: September 2018
  Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)